Interesting the additional distribution agreements (IV house and Mecury Medical) could definitely have been individual announcements in their own right.
When adding this to the Arda distribution, Dualcap & AceeVac product line launch and there is potential for a meaningful increase in revenue over the next few quarters as these move from trials and testing, to hospital acceptance and orders. The admin and sales costs in the preparation for providing these product lines has been incurred the past FY, so with a bit of patience hopefully we will be seeing some sizeable orders this coming FY17.
all IMO, DYOR etc...
MLA Price at posting:
5.0¢ Sentiment: Buy Disclosure: Held
